Warpsolution’s Space:on Achieves FCC Part 18 Certification, Advancing Wireless Charging

Seoul, Korea – September 26, 2024 – (SeaPRwire) – As CES 2025 approaches, Warpsolution’s Space:on has received FCC Part 18 certification, enhancing its market potential by enabling efficient power delivery across any distance without limitations. Revolutionizing Wireless Charging FCC Part 18 certification marks a key advancement for Space:on, setting it apart…

Osaka Gas and MHI to Implement the CO2NNEX Digital Platform for Managing and Transferring the Environmental Value of e-Methane at Expo 2025 Osaka, Kansai, Japan

TOKYO, Sept 25, 2024 - (JCN Newswire via SeaPRwire.com) - Osaka Gas Co., Ltd. (Osaka Gas) and Mitsubishi Heavy Industries, Ltd. (MHI) today announced their agreement to implement CO2NNEX®, the city gas industry's first digital platform for visualizing traded carbon dioxide (CO2) at Expo 2025 Osaka, Kansai, Japan (the Expo).…

Hitachi Rail Unveils the ‘HMAX’ AI Solution, Accelerated by NVIDIA, to Optimize Trains, Signaling and Infrastructure

LONDON, Sept 25, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi Rail’s digital asset management suite – powered by NVIDIA AI technology – launches today and is transforming the way transport operators run and maintain railways.The HMAX (Hyper Mobility Asset Expert) suite is an all-in-one digital asset management platform that…

Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis

Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection 25 mg” (mecobalamin) in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. In May 2022, it received orphan drug designation, and…

Anticancer Agent “Tasfygo(R) Tablets 35mg” (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements

TOKYO, Sept 24, 2024 - (JCN Newswire via SeaPRwire.com) - Anticancer Agent “Tasfygo(R) Tablets 35mg” (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or RearrangementsEisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine…

Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into “Next-generation Convenience Store”

TOKYO, Sept 20, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Corporation (MC), KDDI Corporation (KDDI), and Lawson, Inc (Lawson) will launch an initiative to transform Lawson into "Next-generation Convenience Store " As the COVID-19 changed customers' lifestyles, consumption behaviors, and values, Lawson has been adapting to the “new normal”…